Serban Negoita

Areas of Expertise:

  • Cancer registry operations
  • Cancer data quality assessments
  • Racial/ethnic disparities in cancer treatment

Serban Negoita has joined the Surveillance Research Program as Chief of the Data Quality, Analysis, and Interpretation Branch (DQAIB). He works with the SEER registries and SRP’s experts to enhance the quality of cancer surveillance data. As Branch Chief, he facilitates DQAIB’s mission to provide leadership in cancer data collection, quality improvement, education, analysis, interpretation, and reporting of the cancer burden.

Serban earned his MD from the University of Medicine and Pharmacy in Bucharest, Romania and his DrPH from the State University of New York. During his 25 years in cancer surveillance and public health research, Dr. Negoita served in various roles such as Resident of preventive medicine, Epidemiologist for environmental health and chronic disease surveillance, Research Scientist at the New York State Cancer Registry, and Director of Operations for the Maryland Cancer Registry.

Dr. Negoita’s long-standing career includes many experiences worthy of note. While in Romania, he conducted surveillance of leukemia and lymphoma incidence for the International Agency for Research on Cancer (IARC) following the Chernobyl disaster. During his tenure at the previously non-certified Maryland Cancer Registry, Dr. Negoita and his talented staff achieved NAACCR gold certification four times. He led a variety of cancer treatment analysis projects for federal clients. During that time, Dr. Negoita also had the opportunity to work with NCI SRP staff on a number of data quality control projects.

As an expert in cancer registry operations and data quality assessments, Dr. Negoita anticipates that novel cancer technologies will require new quality assurance procedures and data quality measures. His experience in public health and oncology will complement and enhance DQAIB’s ability to implement technologies and tools developed by the SRP research team and its partners to strengthen and facilitate precision cancer surveillance.

Last Updated: 02 Mar, 2020